GYRE THERAPEUTICS INC COM - Stock (CBIO)

CUSIP: 14888D208

Q1 2020 13F Holders as of 31 Mar 2020

Type / Class
Equity / Stock
Total 13F shares
10,754,400
Share change
+3,201,477
Total reported value
$46,999,275
Put/Call ratio
69%
Price per share
$4.37
Number of holders
45
Value change
+$11,408,286
Number of buys
29
Number of sells
22

Quarterly Holders Quick Answers

What is CUSIP 14888D208?
CUSIP 14888D208 identifies CBIO - GYRE THERAPEUTICS INC COM - Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of GYRE THERAPEUTICS INC COM - Stock (CBIO) as of Q1 2020

As of 31 Mar 2020, GYRE THERAPEUTICS INC COM - Stock (CBIO) was held by 45 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 10,754,400 shares. The largest 10 holders included Nantahala Capital Management, LLC, ACUTA CAPITAL PARTNERS, LLC, MILLENNIUM MANAGEMENT LLC, Stonepine Capital Management, LLC, DIMENSIONAL FUND ADVISORS LP, 22NW, LP, VANGUARD GROUP INC, CITADEL ADVISORS LLC, Prosight Management, LP, and J. Goldman & Co LP. This page lists 45 institutional shareholders reporting positions in this security for the Q1 2020 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.